OTC · LMMY
Consumer Defensive · Education & Training Services
$0.01
Up+$0.00 (+0.00%)
Updated Nov 5, 2026, 6:39 AM
SID Score
2.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LMMY
1M range · 0 trading sessions · Daily adjusted prices
LMMY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning LMMY.
Company
Market Activity
Research & News
LMMY research
Company profile and research snapshot.
L A M Y
Consensus and target data currently published for this company.
No generated briefing is available yet.
Benzinga · Dec 2, 2025
LAMY has acquired Exousia AI, Inc. in an all-stock transaction, securing two exclusive worldwide licenses for exosome technology and receiving an Orphan Drug Designation from the FDA for its Glioblastoma therapy.
accessnewswire.com · Dec 2, 2025
ORLANDO, FLORIDA / ACCESS Newswire / December 2, 2025 / Exousia Pro, Inc. (OTCID:MAJI), a clinical-stage biotechnology company focused on advanced exosome-based delivery systems, today announced the execution of an exclusive licensing agreement between its wholly owned subsidiary, Exousia Pro Holding Management, LLC, and the University of Central Florida (UCF) concerning its groundbreaking technology for both the diagnosis and treatment of cancer using exosomes. Securing Foundational, Worldwide Intellectual Property The agreement grants Exousia Pro Holding Management (EPHM) an exclusive license to UCF-developed patented and patent-pending intellectual property.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LMMY.
No results
No recent SID articles mention LMMY.
